Halozyme Therapeutic (HALO)

Apr 24, 2025, 8:30 AM EDT - 3 days ago

Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation

Apr 10, 2025, 6:15 PM EDT - 17 days ago

Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy

Apr 9, 2025, 8:45 AM EDT - 18 days ago

European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility

Apr 7, 2025, 9:29 AM EDT - 20 days ago

European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Mar 31, 2025, 8:30 AM EDT - 27 days ago

Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid Tumor Indications

Mar 21, 2025, 7:35 AM EDT - 5 weeks ago

Halozyme Joins the $1 Billion Club

Feb 26, 2025, 8:30 AM EST - 2 months ago

Halozyme to Participate in the TD Cowen 45th Annual Healthcare Conference

Feb 18, 2025, 7:55 PM EST - 2 months ago

Halozyme Therapeutics, Inc. (HALO) Q4 2024 Earnings Call Transcript

Feb 18, 2025, 4:01 PM EST - 2 months ago

HALOZYME REPORTS FULL YEAR 2024 RECORD REVENUE OF $1.015 BILLION AND EXCEEDS ITS FINANCIAL GUIDANCE FOR ROYALTY REVENUE, ADJUSTED EBITDA AND NON-GAAP DILUTED EPS

Feb 4, 2025, 8:30 AM EST - 2 months ago

Halozyme to Report Fourth Quarter and Full Year 2024 Financial and Operating Results

Feb 3, 2025, 7:30 AM EST - 2 months ago

CHMP Issues Positive Opinion for Subcutaneous RYBREVANT®(amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Jan 8, 2025, 7:00 AM EST - 3 months ago

Halozyme Reiterates 2024 Financial Guidance and Raises 2025 and Multi-Year Financial Guidance

Jan 6, 2025, 8:30 AM EST - 3 months ago

Halozyme to Host Investor Conference Call to Provide Updated 2025 Financial Guidance

Jan 3, 2025, 3:42 PM EST - 4 months ago

Halozyme: 'Accidental' Business Model Has Exciting Upside Opportunities In 2025

Dec 31, 2024, 2:41 AM EST - 4 months ago

Halozyme: Recent Approvals Alter My Appetite

Dec 30, 2024, 7:00 AM EST - 4 months ago

Halozyme Announces Takeda Received Regulatory Approval for HYQVIA® 10% Subcutaneous Injection Set with ENHANZE® in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

Dec 30, 2024, 6:45 AM EST - 4 months ago

Halozyme Announces argenx's VYDURA with ENHANZE® was Granted Regulatory Approval in Japan for Chronic Inflammatory Demyelinating Polyneuropathy

Dec 30, 2024, 6:30 AM EST - 4 months ago

Halozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig™ with ENHANZE® for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo® (nivolumab) Indications

Nov 27, 2024, 8:30 AM EST - 5 months ago

Halozyme to Present at Upcoming Investor Conferences

Nov 22, 2024, 8:55 AM EST - 5 months ago

Halozyme withdraws $2.1 bln buyout offer for Evotec

EVO

Nov 22, 2024, 8:35 AM EST - 5 months ago

Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions

EVO

Nov 18, 2024, 4:00 PM EST - 5 months ago

Halozyme CEO: Evotec Is Poised for Growth

EVO

Nov 18, 2024, 7:49 AM EST - 5 months ago

Halozyme says €2 billion takeover of Evotech would create leader in drug discovery

Nov 18, 2024, 7:00 AM EST - 5 months ago

Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec

EVO

Nov 15, 2024, 12:56 PM EST - 5 months ago

Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion

EVO

Nov 14, 2024, 4:15 PM EST - 5 months ago

Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction

EVO

Nov 14, 2024, 4:09 PM EST - 5 months ago

Halozyme weighing buyout of drugmaker Evotec, Bloomberg News reports

EVO

Nov 5, 2024, 12:24 PM EST - 6 months ago

Halozyme: Looking For More Growth Following Record Q3 Earnings

Nov 1, 2024, 11:42 AM EDT - 6 months ago

Halozyme Announces Record Earnings, Guidance

Oct 31, 2024, 7:39 PM EDT - 6 months ago

Halozyme Therapeutics, Inc. (HALO) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 4:01 PM EDT - 6 months ago

HALOZYME REPORTS THIRD QUARTER 2024 FINANCIAL AND OPERATING RESULTS

Oct 24, 2024, 6:30 AM EDT - 6 months ago

HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE

Oct 23, 2024, 4:30 PM EDT - 6 months ago

Halozyme to Report Third Quarter 2024 Financial and Operating Results

Oct 8, 2024, 4:12 AM EDT - 7 months ago

Wells Fargo Downgrades Halozyme Therapeutics (HALO) Due to Limited Upside

Oct 3, 2024, 8:00 AM EDT - 7 months ago

Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx for ENHANZE®

Sep 17, 2024, 8:00 AM EDT - 7 months ago

Kaskela Law LLC Announces Shareholder Investigation of Halozyme Therapeutics, Inc. (HALO) and Encourages Investors to Contact the Firm

Sep 13, 2024, 1:30 PM EDT - 8 months ago

Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™ with ENHANZE® for People with Relapsing and Primary Progressive Multiple Sclerosis

Sep 12, 2024, 8:00 PM EDT - 8 months ago

Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for Multiple Types of Cancer

Aug 26, 2024, 7:53 AM EDT - 8 months ago

Top 2 Health Care Stocks That May Plunge In August

ONC

Aug 23, 2024, 6:33 PM EDT - 8 months ago

Final Trade: LULU, VIK, HALO, CCJ

LULU CCJ VIK

Aug 23, 2024, 3:03 PM EDT - 8 months ago

Halozyme Earnings, Guidance Point to Bullish Future

Aug 14, 2024, 2:58 AM EDT - 9 months ago

Halozyme Therapeutics, Inc.: Significantly Undervalued Growth Based On Current Fundamentals

Aug 6, 2024, 11:44 PM EDT - 9 months ago

Halozyme Therapeutics, Inc. (HALO) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 4:01 PM EDT - 9 months ago

HALOZYME REPORTS SECOND QUARTER 2024 FINANCIAL AND OPERATING RESULTS

Jul 23, 2024, 8:30 AM EDT - 9 months ago

Halozyme to Report Second Quarter 2024 Financial and Operating Results

Jul 16, 2024, 5:11 PM EDT - 10 months ago

Big Money Eyes Halozyme for Strong Growth

Jun 25, 2024, 1:15 AM EDT - 10 months ago

Halozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis

Jun 21, 2024, 5:15 PM EDT - 11 months ago

Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo Co-Formulated with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy

Jun 6, 2024, 8:30 AM EDT - 11 months ago

Halozyme Raises Full Year 2024 Financial Guidance and Updates 5-Year Financial Outlook

Jun 5, 2024, 4:05 PM EDT - 11 months ago

Halozyme Announces Issuance of New European Patent for ENHANZE® Drug Delivery Platform